INFED PACKAGE INSERT PDF

Faet Patients with hemoglobinopathy and other refractory anemias that might be erroneously diagnosed as iron deficiency anemias are at particular risk for such iron overload. To avoid injection or leakage into the subcutaneous tissue, a Z-track technique displacement of the skin laterally prior to injection is recommended. The table and formula described under I. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA. Patients who require parenteral nutrition for a limited period of time and who are not iron-deficient do not need parenteral iron supplementation.

Author:Zololkree Dusar
Country:Albania
Language:English (Spanish)
Genre:Music
Published (Last):1 November 2015
Pages:100
PDF File Size:9.72 Mb
ePub File Size:14.37 Mb
ISBN:797-9-64922-232-4
Downloads:73594
Price:Free* [*Free Regsitration Required]
Uploader:Zugore



Vurisar Major Parenteral iron formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory. Periodic hematologic determination hemoglobin and hematocrit is a simple and accurate technique for monitoring hematological response, and should packaeg used as a guide in therapy. Although serum ferritin is usually a good guide to body iron stores, the correlation of body iron stores and serum ferritin may not be valid in patients on chronic renal dialysis infex are also receiving iron dextran complex.

Total dosage with iron dextran must be individualized according to the patients age, weight, and the degree of the iron-deficiency anemia. Severe Deferoxamine chelates iron from ferritin or hemosiderin.

Iron content of hemoglobin. A test dose should be given prior to administration of the initial therapeutic dose. Iron dextran is classified in FDA pregnancy risk category C. Iron dextran should be administered to pregnant women only if the benefits outweigh the potential risks to inged fetus. Infants 4 months and older weighing less than 5 kg. Inject packae slow IV at a gradual rate not to exceed 50 mg 1 mL per minute for adults; take care to inject dosage very slowly in children and infants.

Isoproterenol or similar beta-agonist agents may be required in these patients. Specific guidelines for dosage adjustments in hepatic impairment are not available. If test dose uneventful, give the remainder of the total dose as 50 mg of iron dextran per day IM or slow IV until the total calculated dose is given. Adults, Adolescents, Children, and Infants 4 months and older.

Because anaphylactic reactions are known to occur after uneventful test doses, subsequent test doses should be considered. Patients with a history of drug allergy may be at increased risk for anaphylactoid reactions.

Removal of Iron Dextran by Hemodialysis: The factors that affect the risk for anaphylactic-type reactions to iron dextran products are not fully known but limited clinical data suggest the risk may be increased among patients with a history of drug allergy or multiple drug allergies. Safety and efficacy have not been established. Because anaphylactic reactions are known to occur after uneventful test doses, test doses before subsequent doses should be considered. Anemia, hemochromatosis, hemoglobinopathy, hemosiderosis.

Give INFeD test doses gradually ppackage at least 30 seconds. Reactions are usually evident within a few minutes of administration; however, observe patients for at least 1 hour after the administration of the test dose before administering the remainder of the therapeutic dose. Patients with rheumatoid arthritis may have an acute exacerbation of packqge pain and swelling following the administration of INFeD. The type of anemia and the underlying cause or causes should be determined before starting therapy with parenteral iron dextran.

There is no destructive metabolism of iron because it takes place in a closed system. Such iron overload is particularly apt to occur in patients with hemoglobinopathies and other refractory anemias that might be erroneously diagnosed as iron deficiency anemias. Consult specialized references for amount of test dose to be given.

In general, iron supplementation should not begin in premature infants until adequate vitamin E is supplied in the diet; human breast milk and modern infant formulas usually supply adequate dietary vitamin E. Some patients received epoetin in conjunction with parenteral iron.

Therefore, the pwckage prescription use of iron is usually compatible with breast-feeding if the lactating mother needs treatment for iron deficiency. Patients with preexisting cardiac disease may inserg exacerbation of cardiovascular symptoms if adverse effects occur following iron dextran administration.

Do not add therapeutic doses of iron dextran to total parenteral nutrition TPN solutions; iron dextran may destabilize the mixture or cause the cracking of the TPN emulsion. Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.

Infants and Children 4 months and older weighing less than 15 kg. Epinephrine should be immediately available in the event of acute paackage reactions. Although anaphylactic reactions known to occur following INFeD administration are usually evident within a few minutes or sooner, it is recommended that at least an hour or longer elapse before the remainder of the initial therapeutic dose is given.

Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. Serious anaphylactoid reactions require appropriate resuscitative measures. Evaluate transferrin saturation and serum ferritin before and during epoetin alfa treatment.

However, trace amounts of unmetabolized iron dextran are excreted in breast milk. If test dose uneventful, infuse the remainder of the total calculated dose see equation IV over 2 to 6 hours.

A test dose of 25 mg infused over 5 minutes should be given. The total amount of INFeD in mL required to treat the anemia and replenish iron stores may be approximated as follows:.

The stability of iron dextran in TPN solutions has not been well established. Facilities for cardiopulmonary resuscitation and personnel trained in insfrt detection insetr treatment of anaphylactoid reactions must be available during administration. Since deferiprone has the potential to bind polyvalent cations e.

Adult men, Adolescent males, and Postmenopausal women. Parenterally administered iron does not give a faster response compared to oral administration, therefore, the rate of recovery from anemia should be the same. Related Posts.

HAROLD SCHECHTER DEVIANT PDF

[email protected]: FDA-Approved Drugs

Always have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during INFeD administration. Prior to the first therapeutic dose, administer a test INFeD dose of 0. Although reactions are usually evident within a few minutes, observe patients for at least one hour before administering the therapeutic dose. During all INFeD administrations, observe patients for signs or symptoms of anaphylactic-type reactions.

JURNAL APENDIKTOMI PDF

INFED PACKAGE INSERT PDF

Fatal reactions have followed the test dose of iron dextran injection. Fatal reactions have also occurred in situations where the test dose was tolerated. Circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores. Dextran, a polyglucose, is either metabolized or excreted.

DG508 DATASHEET PDF

BOXED WARNING

Vurisar Major Parenteral iron formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory. Periodic hematologic determination hemoglobin and hematocrit is a simple and accurate technique for monitoring hematological response, and should packaeg used as a guide in therapy. Although serum ferritin is usually a good guide to body iron stores, the correlation of body iron stores and serum ferritin may not be valid in patients on chronic renal dialysis infex are also receiving iron dextran complex. Total dosage with iron dextran must be individualized according to the patients age, weight, and the degree of the iron-deficiency anemia. Severe Deferoxamine chelates iron from ferritin or hemosiderin. Iron content of hemoglobin.

Related Articles